Next-generation bio-integrated neural & systemic interface platform. Engineered for seamless human-machine symbiosis, long-term biostability, and AI-driven adaptive telemetry.
Implantables-8 utilizes a decoupled hardware/firmware architecture, enabling targeted clinical deployment while maintaining a unified telemetry backbone.
Carbon-nanotube micro-electrode arrays with sub-millimeter spatial resolution. Supports bidirectional stimulation and real-time neural decoding.
Harvests kinetic & thermal energy from host physiology. Eliminates external charging requirements with 99.8% energy conversion efficiency.
Quantum-resistant encryption with hardware-level key provisioning. Compliant with HIPAA, GDPR, and IEC 81001-5-1 medical cyber standards.
Immune-modulating surface coating reduces fibrous encapsulation. Maintains signal fidelity over decade-long deployments.
Low-power neural processing unit runs predictive diagnostics & adaptive stimulation algorithms locally. Edge-first architecture.
Open clinical API for third-party device integration. Supports FDA-cleared peripherals, research tools, and hospital EHR systems.
Deep brain stimulation for Parkinson's, epilepsy, and treatment-resistant depression. Closed-loop adaptive pacing reduces symptom variability by 74%.
Retinal & cochlear integration pathways. Multi-channel prosthetic control with tactile feedback loops for upper-limb amputees.
Continuous interstitial fluid analysis for insulin-responsive populations. Predictive hypo/hyperglycemia alerts with 92.6% accuracy.
Hazardous environment worker protection. Thermal regulation, toxin detection, and real-time physiological stress monitoring.
Cognitive enhancement & fatigue resistance tracking. Classified telemetry pipelines for aerospace and field operations.
Multi-institutional data pooling for neuroscience, cardiology, and immunology studies. De-identified dataset export via Zenth Health Cloud.
Implantables-8 adheres to the most rigorous global medical device standards. All clinical pathways are independently audited and FDA/CE registered.
12-center multi-national trial. 98.2% retention rate. Statistical significance achieved for primary endpoints.
PMA submission to FDA. CE technical file finalization. Independent panel peer review completed.
Controlled deployment to partner academic hospitals & specialized clinical centers. SDK v1.0 launch.
Manufacturing capacity expansion. Insurance pathway optimization. Enterprise & defense contracts activation.
For accredited research institutions, surgical centers, and enterprise partners. All inquiries are handled under strict NDA protocols.